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ABSTRACT
The tumor microenvironment is emerging as a key regulator of cancer growth and 
progression, however the exact mechanisms of interaction with the tumor are poorly 
understood. Whilst the majority of genomic profiling efforts thus far have focused 
on the tumor, here we investigate RNA-Seq as a hypothesis-free tool to generate 
independent tumor and stromal biomarkers, and explore tumor-stroma interactions by 
exploiting the human-murine compartment specificity of patient-derived xenografts 
(PDX). 
Across a pan-cancer cohort of 79 PDX models, we determine that mouse stroma 
can be separated into distinct clusters, each corresponding to a specific stromal cell 
type. This implies heterogeneous recruitment of mouse stroma to the xenograft 
independent of tumor type. We then generate cross-species expression networks 
to recapitulate a known association between tumor epithelial cells and fibroblast 
activation, and propose a potentially novel relationship between two hypoxia-
associated genes, human MIF and mouse Ddx6. Assessment of disease subtype also 
reveals MMP12 as a putative stromal marker of triple-negative breast cancer. Finally, 
we establish that our ability to dissect recruited stroma from trans-differentiated 
tumor cells is crucial to identifying stem-like poor-prognosis signatures in the tumor 
compartment. 
In conclusion, RNA-Seq is a powerful, cost-effective solution to global analysis of 
human tumor and mouse stroma simultaneously, providing new insights into mouse 
stromal heterogeneity and compartment-specific disease markers that are otherwise 
overlooked by alternative technologies. The study represents the first comprehensive 
analysis of its kind across multiple PDX models, and supports adoption of the approach 
in pre-clinical drug efficacy studies, and compartment-specific biomarker discovery.
INTRODUCTION
The tumor stroma comprises of numerous cell types 
including endothelial cells, cancer-associated fibroblasts 
(CAFs), mesenchymal stem cells, and immune cells such 
as lymphocytes and tumor-associated macrophages. It 
plays a critical role in supporting cancer growth and 
metastasis [1], and is therefore emerging as rich source 
of targets for anti-cancer therapy. However, we have a 
poor understanding of the interactions between tumor 
and stroma. A typical solid tumor tissue sample consists 
of both components, and such sample heterogeneity can 
have significant influence on the biological interpretation 
of genomic profiling studies [2]. Furthermore, attempts 
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to separate tumor from stroma are hampered by the 
requirement for specialist techniques such as laser capture 
micro-dissection, with small amounts of tumor cell 
contamination possible.
Patient-derived tumor xenograft (PDX) models are 
generated when fresh tumor tissue obtained directly from 
patients is implanted subcutaneously or orthotopically 
into immune-deficient mice. As such, they maintain the 
principal histological, clinical and molecular characteristics 
of the original patients’ tumors while remaining biologically 
stable when passaged in mice [3–5]. Since PDX models 
more closely resemble and recapitulate tumor growth in 
humans than standard in vitro cell line or cell line xenograft 
approaches, they remain key experimental platforms for 
pre-clinical drug development.
Recent studies have shown that human and 
mouse transcription can be accurately differentiated in 
PDX models using RNA-Seq [6–7], removing the need 
for manipulation of the RNA population, customised 
sequencing protocols, or prior knowledge of the species 
component ratio. Moreover, the known transcriptional 
response to drugs targeting the stroma can be accurately 
recapitulated in both human tumor and mouse stroma [6]. 
The high specificity of the in silico read disambiguation 
approach means that gene expression in the human 
component is quantified almost exclusively from tumor 
RNA, particularly in later passages where the original 
patient stroma has been replaced by mouse stroma. Thus 
PDX transcriptome data provide a unique opportunity for 
the simultaneous study of both tumor and stromal specific 
signals in vivo. Consequently, several studies have adopted 
the approach albeit restricted to only a small number of 
xenograft models or specific cancer type [8–9]. 
In this paper, we build significantly on these early 
studies by using RNA-Seq to profile the baseline human 
and mouse transcriptome of 79 PDX models representing 
multiple cancer types. By doing so, we assess mouse 
stromal heterogeneity, generate hypotheses on the 
relationship between mouse stroma and human tumor, 
and identify both tumor and stromal specific markers of 
disease subtype. To our knowledge, this represents the first 
comprehensive analysis of both species components of 
PDX models simultaneously across such a large cohort. As 
such, the dataset should provide a key platform for gaining 
additional insights into PDX tumor and stroma processes, 
and interpreting pre-clinical efficacy studies. 
RESULTS
79 PDX models from five different providers covering 
seven cancer types were used in the study (Figure 1A, 
Table S1) with the majority of models representing lung 
(37 models) and breast (19 models). A mean of 47,906,117 
human and 6,612,995 mouse reads were uniquely mapped 
to a concatenated human and mouse genome (Figure S1A, 
Table S2), corresponding to a human component of ~88% 
in each sample (Figure S1B, Table S2). We have previously 
demonstrated that low coverage (1.3–2.0 M reads) was 
sufficient to deliver accurate detection and measurement of 
mouse gene expression [6]. In this study we generated a 
coverage of 5–10 M reads, which was considered sufficient 
to generate a robust data set. Expression between technical 
and biological replicates showed strong correlation 
across both human (Figure S2A–S2C) and mouse (Figure 
S2D–S2F) genes. Predicted stromal and immune 
cell content using ESTIMATE [10] indicated a clear 
differentiation between the human and mouse components, 
and > 97% tumor purity in the human component of 76/79 
samples (Figure S3, Table S3). As a proxy for the quantity 
of original patient stroma in each PDX sample, human 
expression levels of two CAF markers that are rarely 
expressed by tumor epithelial cells, fibroblast activation 
protein alpha (FAP) and chondroitin sulfate proteoglycan 4 
(CSPG4), were assessed. 22/79 samples showed evidence 
of patient stroma retention at a low stringency CAF marker 
expression threshold (FAP or CSPG4 log
2
 FPKM > 2.0; 
Table S3) and therefore flagged as potential confounders 
in analyses of the human component. Of these, only 11 
samples expressed high levels of either marker (log
2
 
FPKM > 4.0), and overall results suggest human and mouse 
transcriptional profiles reflect highly enriched human tumor 
and mouse stroma cell populations respectively in the 
majority of samples.
Mouse stroma heterogeneity is primarily driven 
by dominant cell type 
We applied non-negative matrix factorization (NMF) 
to cluster 14173 and 3933 of the most highly expressed 
(human: FPKM > 10, mouse: FPKM > 2 in at least one 
sample) and variable (coefficient of variation > 0.20) genes 
across human and mouse respectively, and test whether 
gene expression signatures exist in the mouse component 
allowing separation into distinct subtypes. Stable clusters 
were achieved at k = 9 (human; Figure 1B) and k = 5 
(mouse; Figure 1D) where k denotes the number of clusters 
and values selected according to the procedure outlined in 
Methods. Model-to-cluster mappings for both human and 
mouse are given in Tables S4A and S4B respectively, and 
genes deemed as key drivers of the clustering (meta-genes) 
are listed in Tables S5A (human) and S5B (mouse).
Human clusters were more strongly associated with 
cancer type (p < 2.20E-16 by Chi-squared test; Figure 1C) 
than the mouse clusters (p = 1.07E–5; Figure 1E). 8/15 
and 7/11 tumors in human clusters 1 and 2 respectively 
expressed CAF markers FAP/CSPG4, which may suggest 
a propensity for some lung squamous and triple-negative 
breast cancers (TNBC) to retain patient stroma.
Functional enrichment analysis using Toppgene 
[11] revealed that 3/5 mouse clusters encompassed strong 
functional themes associated with fat (cluster 1), muscle 
(cluster 3) and immune cells (cluster 5; Figure 1F, Table S6) 
corresponding to strong overlap with adipocyte 
(p = 1.70E–16), embryonic stem (p = 2.14E–37), and 
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myeloid (p = 8.68E–28) cell type signatures respectively. 
Cluster 2 was primarily driven by Col10a1 expression 
(relative contribution to meta-gene = 0.89; Table S5B), a 
potential marker of CD10+ tumor stromal cells [12], and 
cluster 4 showed some enrichment for mesenchymal stem 
cell markers (p = 1.01E–08). 
The mean number of mapped mouse reads (Figure S4A) 
or proportion of mouse component (Figure S4B) was not 
significantly different between mouse clusters. Notably, 
cluster 5 included samples from model HOXF060 with 
the largest mouse component in the cohort (69.8%; 
35,614,081 mapped reads), and HPAXF049 with one of 
the lowest mouse components (7.5%; 3,109,853 mapped 
reads). Despite the difference in coverage, high mouse gene 
expression correlation was achieved between these samples 
(r = 0.93; Figure S5), suggesting coverage was not a major 
confounding factor. Furthermore, no significant association 
was observed between the mouse clusters and mouse gender 
(p = 0.10) or tumor stage (primary or metastatic; p = 0.55), 
and only some association with mouse strain (p = 3.09E–04). 
This was possibly driven by membership of all athymic 
nude mice in clusters 1 and 4 (Figure 1E), otherwise, it was 
difficult to discern possible influence of mouse strain on 
dominant stromal cell type from these data alone.
Inferring tumor-stroma crosstalk from inter-
species gene expression correlations
Given the potential for heterogeneous recruitment 
of mouse stroma to the human tumor, we next performed 
a comprehensive expression correlation analysis between 
human and mouse components to generate hypotheses on 
tumor-stroma crosstalk. We initially looked for evidence 
of a known tumor-stroma association, selecting the recent 
observation that fibroblast activation is associated with 
a tumor epithelial cell type [13]. Expression of human 
epithelial cadherin (CDH1) and epithelial cell adhesion 
molecule (EPCAM) were used as epithelial markers, and 
mouse expression of fibroblast associated protein (Fap), 
chondroitin sulfate proteoglycan 4 (Cspg4) and alpha-
smooth muscle actin (Acta2) as CAF markers. In five of 
the six possible cross-species comparisons, a significant 
Pearson correlation coefficient (p < 0.05) was observed 
between the human epithelial and mouse CAF markers 
(Table 1; Figure S6A–S6F), particularly between EPCAM 
and Fap (r = 0.37, p = 7.90E–4; Figure S6A) indicating the 
positive relationship between tumor epithelial cell type and 
fibroblast activation exists in the PDX panel. No significant 
correlation was observed between the mouse CAF markers 
Figure 1: Application of non-negative matrix factorization (NMF) to optimal clustering of human and mouse 
gene expression. (A) disease representation across the 79 PDX models. (B) consensus matrix at k = 9 for the human transcriptome. 
(C) contributing cancer types and mean consensus value of each human cluster. “Representative” disease indicates the majority cancer type 
in the cluster, and numbers of models are given in brackets. Mean consensus value was computed from 200 runs of NMF. (D) consensus 
matrix at k = 9 for the mouse transcriptome. (E) meta-data breakdown in each mouse cluster and mean consensus value. (F) functional 
enrichment of the meta-genes driving the mouse clustering. Only clusters with significant functional enrichment (FDR < 0.05) are shown. 
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and two human mesenchymal cell type markers vimentin 
(VIM) and zinc finger E-box binding homeobox 1 (ZEB1; 
Table 1), with Fap achieving weak anti-correlation with 
both VIM (r = −0.20, p = 0.08) and ZEB1 (r = −0.21, 
p = 0.06). Within the context of all correlations between 
human CDH1 and 2495 most highly expressed and variable 
mouse genes, both Fap and Cspg4 were ranked in the top 
6% most correlated genes (Table S7). Notably, a significant 
number of these top 6% genes play a role in cell migration 
(p = 8.37E–13) and vasculature development (p = 3.12E–10), 
both characteristic of an activated stroma, including the top 
ranked gene collagen, type VIII, alpha 1 (Col8a1, r = 0.67; 
Figure S7), a key component of blood vessel endothelia.
To explore potentially novel gene-wise associations 
between human tumor and mouse stroma, an all-against-
all comparison of 14,336 expression profiles representing 
the most highly expressed and variable genes from both the 
human (11,841 genes) and mouse (2495) components was 
performed. The resulting co-expression network consisted 
of 259,627 edges and 7089 nodes (Figure 2A) where 
nodes represented genes and edges were drawn between 
gene pairs achieving a stringent threshold of |r| > 0.85 
(p < 2.20E–16) to control for false positives. The majority of 
edges (256,922) were between positively correlated human 
gene pairs, with the remainder of the network comprising of 
2661 edges between mouse gene pairs, and 44 cross-species 
anti-correlated gene pairs. The strongest cross-species 
anti-correlation (r = −0.90) was observed between human 
macrophage migration inhibitory factor (MIF) and mouse 
DEAD-box RNA helicase 6 (Ddx6) (Figure 2B). In addition, 
human MIF (connected to 17 mouse genes) and mouse 
Ddx6 (connected to 8 human genes) represented the most 
connected cross-species nodes in the network (Table S8). 
Increased MIF expression and reduced DDX6 
expression are both known drivers of angiogenesis and 
strongly associated with VEGF activity, as such they have 
been implicated in tumor response to hypoxia [14–15]. 
Consistent with their known roles, positively correlated first 
or second neighbors of MIF in the network (Figure 2A) were 
enriched for mitochondrial processes (p = 7.15E–05) and 
oxidative phosphorylation (p = 1.72E–04), whereas mouse 
genes neighboring Ddx6 were enriched for other RNA 
binding genes (p = 3.93E–08). To test the association with 
hypoxia more explicitly, models were divided into MIF high/
Ddx6 low (log
2
 FPKM human MIF > 11.5, mouse Ddx6 
< 1.05) and MIF low/Ddx6 high (MIF < 7.0, Ddx6 > 1.8) 
corresponding to possible hypoxic and normoxic samples 
respectively (Table S9). Genes differentially expressed (log
2
 
fold change (FC) > 1.50, false discovery rate (FDR) < 0.05) 
between the two groups were then identified. According 
to Toppgene, genes over-expressed in MIF high/Ddx6 
low samples were enriched (p = 1.50E–06) for signatures 
representing genes up-regulated under hypoxia in vivo [16]. 
Conversely, genes over-expressed in MIF low/Ddx6 high 
samples were enriched (p = 5.09E–05) for genes down-
regulated in the same study, thus supporting the association 
of high human MIF and low mouse Ddx6 expression with 
tumor hypoxia.
Closer inspection of all possible inter- and intra-
species correlations between MIF and DDX6 (Figure 2C) 
revealed no significant association (p < 0.01) between 
human DDX6 and either human MIF (r = 0.23, p = 0.04), 
mouse Ddx6 (r = −0.04, p = 0.75), or mouse Mif (r = −0.17, 
p = 0.14). By contrast, human MIF and mouse Mif achieved 
the second highest correlation (r = 0.72) between human and 
mouse orthologs, suggesting that MIF has complementary 
roles in the tumor and mouse stroma.
PDX models as a source of tumor and stroma 
specific markers of disease subtype
We next focused on lung and breast cancer as the 
two most highly represented diseases in the PDX cohort, 
in order to assess the potential of our approach to identify 
clinically relevant, independent human tumor and mouse 
stroma markers of disease subtype. 
Table 1: Pearson correlation coefficients calculated between human epithelial and mouse CAF 
markers
Human genes
Mouse genes
Acta2 Fap Cspg4
CDH1 0.29** 0.24* 0.32**
EPCAM 0.06 0.37** 0.27*
VIM 0.01 −0.20 0.10
ZEB1 −0.01 −0.21 −0.05
**p < 0.01, *p < 0.05
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Stromal-specific markers of lung and breast 
cancer subtype
Comparison between mouse components of 14 
lung adenocarcinomas and 18 squamous carcinomas 
identified no significantly differentially expressed genes, 
suggesting uniform recruitment of mouse stroma to human 
lung xenografts. By contrast, in the breast cancer panel, 
18 mouse genes achieved significant fold change (|log2 
FC| > 1.5, FDR < 0.05) between four ER+ luminal-B and 
nine basal-like TNBCs (BTNBC; Table S10). Such a low 
number of genes is in broad agreement with a dataset of 
patient tumor stroma samples isolated by laser capture 
micro-dissection (Finak_Stroma) [17] in which only 
29 genes were differentially expressed (|log2 FC| > 1.5, 
FDR < 0.05; Table S12). However, there was little overlap 
between the two gene lists with matrix metallopeptidase 
12 (Mmp12) the only gene over-expressed in both mouse 
(log
2
FC = 2.00, FDR = 2.43E–02) and clinical (log
2
FC 
= 2.83, FDR = 3.14E–09) stroma. Interestingly, whilst 
MMP12 expression was largely absent in the PDX human 
component (mean log
2
 FPKM = 0.44) and cell lines of the 
Cancer Cell Line Encyclopaedia [18] (CCLE; mean log
2
 
signal = 4.51) representing pure tumor cell populations 
(Figure 3A), significant over-expression in BTNBC was 
detected in clinical samples from The Cancer Genome Atlas 
[19] (TCGA; log
2
FC = 2.89, FDR = 2.67E–14) and the 
Utah Breast Cancer Study (UBCS; log
2
FC = 2.56, FDR = 
1.21E–02; Figure 3B). Thus significant fold changes appear 
restricted to only those samples containing recruited stroma 
(PDX mouse component, Finak_Stroma, and clinical tumor 
samples), suggesting that MMP12 expression is specific to 
BTNBC stroma, and absent in tumor cells.
Tumor-specific markers of BTNBC
Exploiting the tumor purity of the PDX human 
component, we derived a putative set of tumor-specific 
BTNBC markers by comparing a list of 1127 genes over-
expressed (log
2
FC > 1.5, FDR < 0.05) in BTNBC from the 
PDX human component with 273 genes over-expressed 
(log
2
FC > 1.5, p < 0.001) in cell lines. This resulted in 
an overlap of 117 genes on platforms representing high 
tumor content (Figure 3A). We then performed a second 
overlap between this tumor-specific gene signature and 
6156 differentially expressed genes detected in TCGA 
and UBCS at FDR < 0.05 but ignoring fold change 
magnitude. By doing so, we reasoned that genes unique 
Figure 2: Human MIF and mouse Ddx6 are strongly anti-correlated and are identified as cross-species hubs. 
(A) Cytoscape [59] rendered human (red boxes) and mouse (blue) gene co-expression network where nodes are genes and edges indicate 
gene pairs achieving r > 0.85 (grey) or r < −0.85 (green). Magnified view shows sub-network of first and second neighbors of human MIF 
and mouse Ddx6. (B) scatterplot showing anti-correlation (r = −0.90) between human MIF and mouse Ddx6. (C) r-values between all 
combinations of human/mouse MIF and DDX6 mRNA expression profiles. 
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to the intersection between PDX and cell line datasets 
represented BTNBC markers that could only be observed in 
samples with high tumor purity, and overlooked in clinical 
samples containing a mixture of tumor cells and recruited 
stroma. Five genes fulfilled the criteria (Figure 3C): 
transmembrane glycoprotein NMB (GPNMB), CD44, toll-
like receptor 3 (TLR3), anthrax toxin receptor 1 (ANTXR1) 
and lysyl oxidase (LOX). All five genes retained significant 
differential expression after removal of five breast cancer 
samples (HBCX10, HBCX11, HBCX24, HBCX6 and 
HBCX9) expressing CAF markers FAP/CSPG4 in the 
human component, addressing the possibility that persistent 
retention of patient stroma in the BTNBC PDX models was 
confounding results.
To reproduce the tumor purity of the PDX human 
component and cell lines in clinical samples, we performed 
a second comparison between 12 BTNBC and 10 ER+ 
luminal-B TCGA patients representing samples with 
the highest estimated tumor cell content (ESTIMATE 
stromal score < −700). Remarkably, significant differential 
expression emerged in GPNMB (log
2
FC = 1.19, FDR = 
1.18E–02) and LOX (log
2
FC = 2.07, FDR = 2.53E–05) with 
the fold change of a third gene, ANTXR1 also increasing but 
not to significance (log
2
FC = 0.74, FDR = 0.13; Figure 3D). 
This suggests that at least two of the five genes are BTNBC 
markers expressed in patient samples, whose significance is 
masked by the difficulty of separating recruited stroma from 
tumor cells of stromal phenotype.
Tumor-specific BTNBC markers are enriched for 
genes associated with a stromal phenotype 
To gain further insight into potential BTNBC markers 
derived from high tumor content samples, we next compared 
1127 and 1368 genes over-expressed (log
2
FC > 1.5, FDR 
< 0.05) in BTNBC from the PDX human component and 
TCGA patient samples respectively. This resulted in an 
overlap of 574 genes. 
We initially speculated that the differences between 
the lists could in part be attributed to the presence of 
recruited stroma in typical clinical samples that is absent in 
the PDX human component (Figure 3A), so we included 
a 137-stromal gene signature [10] (Table S13A) in the 
comparison. Surprisingly, we observed greater overlap 
(p = 6.00E–04 by hyper-geometric test) of stromal signature 
genes with BTNBC markers derived from the PDX human 
component than those from clinical samples (p = 1.00; 
Table 2; Figure 3E; Table S14). To understand whether this 
overlap was indicative of specific cell type, we also overlaid 
epithelial-mesenchymal transition [20] (EMT; Table S13B), 
breast cancer stem cell [21] (CSC; Table S13C) and reactive 
stromal [22] (Table S13D) signatures. Clear enrichment 
(p = 7.77E–16) of mesenchymal markers including VIM 
was observed in the BTNBC PDX human component. 
By contrast, only a slight enrichment was observed 
(p = 0.07) in clinical BTNBC samples and whilst 
VIM achieved significant fold change, it was small 
(log
2
FC = 1.13, FDR = 2.15E–15) compared to that 
observed from the PDX human component (log
2
FC = 4.49, 
FDR = 2.18E–05). There was no enrichment of stromal or 
mesenchymal cell markers in genes over-expressed across 
either PDX or clincal ER+ luminal-B samples (Table 2; 
Table S14). The BTNBC PDX human component was 
also enriched for reactive stroma (p = 6.08E–04) and 
breast CSC markers (p = 1.60E–04; Table 2; Table S14), 
and whilst a high number of non-CSC markers were also 
present, the enrichment was not significant (p = 0.53). 
Furthermore, CD44, a marker for cells with tumor initiating 
potential, was identified as a BTNBC marker in both PDX 
(log
2
FC = 2.14, FDR = 5.91E–04) and cell line 
(log
2
FC = 2.58, p = 8.66E–03) but not in clinical 
(log
2
FC = 0.06, FDR = 0.79) datasets. Low CD24 expression 
is also indicative of tumor initiating potential, however 
human CD24 expression was not detected across any of the 
PDX samples. Conversely, non-CSC markers were enriched 
in genes over-expressed in PDX (p  =1.26E–03) and TCGA 
ER+ luminal-B samples (p = 1.29E–05). 
Encouragingly, BTNBC markers remained enriched 
for stromal (p = 3.30E–03), EMT (p = 4.17E–10), CSC 
(p = 1.59E–03) and reactive stromal (p = 3.04E–03) 
signatures (Figure 3F; Table 2; Table S14) after removal 
of the five breast PDX models expressing CAF markers 
FAP and CSPG4 suggesting the presence of stromal-
like signature genes in the PDX human component was 
independent of patient stroma retention. Furthermore, 
there was no evidence of bias towards mesenchymal or 
mesenchymal stem-like (MSL) TNBC subtypes [23] 
(Table S11), indeed no MSL or immunomodulatory (IM) 
subtypes were present in the PDX data in accordance with 
the view that these subtypes are likely defined by high 
expression of genes from the micro-environment rather 
than the tumor itself [24]. Therefore our observations are 
unlikely due to over-representation of the stromal subtype 
in PDX BTNBC models.
Stromal phenotype emerges in BTNBC clinical 
samples of high tumor content
As before, we reproduced the tumor purity of the 
PDX human component in clinical samples by focusing 
on TCGA samples with the lowest predicted stromal cell 
content (ESTIMATE stromal score < −700).  Remarkably, 
enrichment of both EMT (p = 2.05E–07) and CSC 
(p = 1.83E–02) signatures emerged in genes differentially 
expressed between the remaining 12 BTNBC and 10 ER+ 
luminal B TCGA samples, comparable to that observed 
in the PDX human component (Figure 4C). The numbers 
of stromal and reactive stromal signature genes also 
increased although not sufficient to achieve significance. 
Taken together, these findings support the presence of 
a subpopulation of cells with CSC and mesenchymal 
features in BTNBC that is difficult to detect in a typical 
clinical sample due to equivalent expression signals from 
the recruited stroma.
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DISCUSSION
We describe the output of a comprehensive 
expression analysis of 79 pan-cancer PDX models using 
an RNA-Seq generated species-specific mapping strategy. 
Accurate separation of human and mouse components 
of the tumor allows use of PDX tumors to gain unique 
insights into tumor-stroma crosstalk, and through cross 
comparison, generate both tumor and stroma expression 
signatures that give insights specific to disease subtypes, 
and also aid development of biomarker signatures. When 
passaged in vivo much of the patient stroma present 
upon implantation and early passages is eventually 
replaced by murine stroma, and whilst this can lead to 
loss of some original features found in the patient tumor 
microenvironment [25], it is key to enabling non-invasive 
species-specific separation of PDX tumor from stroma 
in silico. Therefore, it offers a unique opportunity not only 
to look at features specific to the stroma but also reveal 
new biology within the human tumor cells.
Identification of distinct mouse stromal clusters 
defined by dominant cell type 
Mouse gene expression profile clustering revealed 
distinct PDX stromal subtypes broadly related to dominant 
cell types characterized by adipocyte, embryonic stem, 
and myeloid signatures, the latter indicating a high level 
of inflammatory infiltrate in the mouse stroma. These were 
independent of cancer type and PDX provider and suggest 
heterogeneous recruitment of mouse stroma to the human 
tumor. Since interaction between the tumor and stroma is 
known to influence drug response, our findings imply that 
the effect of the dominant stromal cell type in an individual 
model should be considered when analyzing therapeutic 
response. This is particularly pertinent for compounds that 
may drive efficacy through stromal elements, or be subject 
to stromal derived resistance. However, whilst the approach 
provides the opportunity to explore the association of 
stromal subtype and the degree of inflammatory infiltrate 
with survival outcome and drug resistance, it is important 
to characterize the models carefully. In this study of 
commonly used models there was a notable enrichment of 
high-grade tumors with poor prognosis [26], which will 
influence the outcome of such studies. 
Human-mouse gene correlation analysis 
identifies both known and potentially novel 
tumor-stroma associations
The degree of transcriptional heterogeneity in the 
mouse component, and the potential for active involvement 
of the xenograft in the process prompted us to look more 
closely at gene expression correlations between the human 
Figure 3: Compartment-specific gene expression markers of BTNBC. (A) comparison of ESTIMATE stromal score between 
PDX, TCGA, CCLE and clinical stroma samples. (B) fold changes achieved by MMP12 between BTNBC and ER+ luminal-B samples 
across all platforms (*p < 0.01). (C) derivation of tumor specific BTNBC markers exclusive to cell line and PDX datasets. (D) emergence of 
tumor specific markers in low stroma TCGA samples (*p < 0.05). (E) overlap of stromal [10], EMT [20], CSC [21] and reactive stroma [22] 
signatures with BTNBC markers derived from human PDX and TCGA samples. (F) comparison of log
10
 p-values achieved across sample 
types by overlap with each of the four signatures (*p < 0.05). CSC: cancer stem cell, EMT: epithelial-mesenchymal transition, MMP12: 
Matrix Metalloproteinase 12.
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and mouse component. This approach identified known 
associations between tumor epithelial cell type and fibroblast 
activation [13], exemplified by significant correlation 
between human epithelial and mouse CAF markers. These 
were amongst several mouse genes correlated with human 
CDH1 including numerous endothelial-associated genes. 
We then applied more stringent criteria to generate a cross-
species correlation network and identify novel associations. 
The strongest relationship was an anti-correlation between 
human MIF and mouse Ddx6. MIF plays an important 
role in the induction of vascular endothelial growth factor 
(VEGF) activity promoting blood vessel growth [27], 
and is also a target of the transcription factor hypoxia-
inducible factor 1-alpha (HIF1α) [14]. Conversely, DDX6 
inhibits VEGF protein expression under normoxia through 
binding to the 5′-UTR of its mRNA [15]. Our data suggest 
a potential stromal role for DDX6 in the hypoxia response 
as an alternative to its previously established tumor-specific 
activity, and a potential link with MIF activity in the tumor.
Overall, our findings highlight the value of RNA-
Seq as a sensitive approach to dissect the complex 
interplay between both species compartments. However 
there are two caveats. Firstly the original tumor-stroma 
interactions in the patient are unlikely to be completely 
recapitulated due to incompatibility of human and mouse 
proteins, and the use of immune-compromised mice to 
promote xenograft establishment. Whether this is major 
caveat remains to be established. Whilst our results suggest 
known interactions develop in PDX models, further work 
will be necessary to establish a direct functional link in 
any novel interaction suggested by these data alone, and 
whether it represents a clinically relevant association or 
one that is unique to the xenograft. Secondly, the majority 
of tumors were implanted subcutaneously providing 
an ectopic environment. Where technically achievable, 
comparison with a more physiological implantation site 
used in orthotopic engraftment may better recapitulate 
the original patient stroma, and as such models become 
more widely available, similar profiling studies should be 
performed on these. 
Stromal gene expression markers of cancer-
subtype
Compared to the transcriptional differences 
observed between lung and breast cancer subtypes within 
the human tumor component, typically involving >1000 
genes, the differences between the mouse stroma were 
small. Indeed, no mouse genes were deemed differentially 
expressed between lung adenocarcinoma and squamous 
mouse stroma, and only 18 mouse genes between breast 
ER+ and TN. This suggests recruitment of mouse stroma 
to the tumor is largely independent of disease subtype.  
The search for stromal specific markers of BTNBC 
also highlighted potential disparities between PDX mouse 
and patient stroma. Whilst there was consensus in terms 
Table 2: Overlap of gene signatures with genes over-expressed in BTNBC and ER+ luminal-B 
breast cancers
Signature
BTNBC ER+ luminal-B
PDX 
(1127a)
PDX FAP/
CSPG4 
low (793a)
TCGA 
(1368a)
TCGA low 
stroma 
(1763a)
PDX 
(511a)
PDX FAP/
CSPG4 low 
(569a)
TCGA 
(876a)
TCGA low 
stroma 
(847a)
Stromal (137b) 20* 14* 2 9 1 5 4 6
CSC Up (90c) 16* 11* 5 16* 2 3 1 1
CSC Down (211c) 14 12 13 18 15* 14* 27* 29*
EMT Up (144d) 41* 27* 17 37* 5 11* 8 11
EM Down (156d) 30* 22* 34* 33* 8 6 21* 21*
Reactive stroma 
(50)
11* 8* 0 6 0 0 1 1
*p < 0.05 by hyper-geometric test.
aNumber of genes over-expressed in TNBC or ER+ luminal-B.
bFrom [10].
cBreast cancer stem cell (CSC) signature from [21].
dEpithelial-mesenchymal transition (EMT) signature from [20]. 
eFrom [22].
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of fewer changes in stroma compared to tumor, only 
MMP12, previously associated with breast cancer poor 
prognosis [17] [28], was detected as a BTNBC marker 
in both PDX mouse and patient stroma. The patient 
stroma clearly reflected changes typically seen in the 
tumor between TNBC and ER+ samples in agreement 
with recent studies suggesting that intrinsic breast cancer 
subtypes can be recapitulated based on the transcriptome 
of cancer adjacent tissue [29–31]. By contrast, there 
was no evidence of subtype reflected in the PDX stroma 
transcriptome but instead genes differentially expressed in 
PDX stroma were enriched in functions characteristic of 
metastasis, a process common to BTNBC. 
Whilst these results could reflect intrinsic differences 
between the patient and mouse stroma, alternatively 
they could be a consequence of the higher predicted 
stromal cell purity achieved with our RNA-Seq approach 
compared to laser capture micro-dissection. Therefore, 
the specificity achieved by RNA-Seq in disambiguating 
human from mouse could offer a significant advantage, 
particularly in combination with a systematic integration 
of clinical datasets such as TCGA to overcome limitations 
of using mouse stroma. For example, evidence for 
MMP12 as a BTNBC stromal marker was strengthened 
by the observation that its expression is absent in samples 
containing only tumor cells, but present in samples that 
typically contain a significant stromal cell component.
Expression signals from recruited stroma could 
mask presence of poor prognosis markers in 
BTNBC 
A major outcome of the disease-specific analysis 
was the identification of a BTNBC stromal signature in the 
PDX human component, not detected in TCGA or UBCS 
clinical samples. This was achieved through the ability of 
RNA-Seq to differentiate the two major sources of cells 
with a stromal phenotype in a typical xenograft sample, 
trans-differentiated tumor cells [32] (human cells) and co-
opted/recruited stroma (mouse cells). In a patient sample, 
this is difficult to accomplish with high confidence, even 
with specialist techniques such as laser capture micro-
dissection, highlighting the capacity of RNA-Seq to 
refine complex signatures that are typically derived from 
heterogeneous cell populations.
The enrichment of breast CSC markers, including 
CD44, and EMT markers such as VIM supports previous 
work that showed EMT and CSC phenotypes are more 
likely to occur in basal breast cancers [33–34]. Notably, 
CD44 was one of five genes previously associated with 
BTNBC and poor prognosis that were clearly over-
expressed in BTNBC PDX human and cell line samples but 
not in clinical samples. Of the other four genes, TLR3 and 
ANTXR1 are also CSC markers [35–36], whilst LOX and 
GPNMB are metastatic markers of BTNBC [37–40]. Given 
the phenotypes associated with these genes, we could have 
uncovered a particularly aggressive sub-population of cells 
analogous to CSCs residual after conventional treatments 
[21] that are present in BTNBC but absent in ER+ luminal-B 
patients. Critically, the observation that CSC and EMT 
gene signatures emerge in BTNBC markers derived from a 
dataset restricted to TCGA samples with the lowest stromal 
cell content strongly suggests that the phenomenon is not 
exclusive to PDX models, and counters the possibility that 
CSCs are simply more successful at engrafting in the mouse 
mammary microenvironment than other cell types [41].
We had two further concerns about our PDX breast 
cancer dataset, firstly BTNBC is over-represented due to 
the difficulty in establishing ER+ tumors in mice [42], 
and secondly, despite the retention of poor prognosis 
markers after removal of five BTNBC PDX models 
expressing CAF markers, we could not completely rule 
out the possibility of persistent patient stroma retention 
confounding the above observations. If this is the case, the 
presence of stromal-associated genes in the BTNBC PDX 
human component could reflect the level of reactive stroma 
in the original patient tumor. This indicates increased 
metastatic capacity leading to disease progression and 
poor prognosis, particularly in BTNBC [43]. Recently, a 
study has shown that increased stroma has the opposite 
effect in ER+ breast tumors [44], and although the results 
have since been challenged [45], a bias towards aggressive 
tumors with poor prognosis in PDX models could lead to 
an enrichment of high stroma BTNBC and low stroma 
ER+ luminal-B tumors in our breast cancer cohort and 
the appearance of stromal-associated genes not present 
in the clinical data. Indeed, ER+ luminal-B tumors are 
themselves distinct from other ER+ subtypes due to their 
aggressive phenotype and resistance to conventional 
hormone therapy [46]. Therefore, the effect of excluding 
mouse stroma is to reveal genes specific to the original 
reactive stroma in the patient. 
One further possibility was we had simply identified 
the presence of a stromal-like BTNBC subtype, however 
we found no evidence of bias towards mesenchymal or 
MSL TNBC subtypes [23] in our breast xenografts, nor in 
our TCGA/UBCS clinical samples of high tumor purity in 
which the signature emerged.
Despite these concerns, the masking of key markers 
of BTNBC by expression signals from recruited stroma 
is a significant observation and clearly illustrates the 
confounding effects of tumor sample heterogeneity 
on differential expression measurements. Considering 
the importance of the genes missed in the clinical 
samples unless stromal recruitment is accounted for, our 
observations have implications for any study that uses 
clinical samples to derive cancer-associated signatures, 
and potentially contribute to the poor overlap observed 
between signatures derived from different studies. They 
also demonstrate the potential of the RNA-Seq approach 
to refine complex signatures whose source compartment 
is ambiguous.
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CONCLUSIONS
This study has established RNA-Seq as a cost-
effective approach to enable simultaneous analysis of 
human tumor and mouse stroma across a pan-tumor explant 
panel. The analytical strategy provided new insights 
into mouse stromal heterogeneity and compartment-
specific disease markers otherwise overlooked by other 
technologies. Whilst further work is necessary to investigate 
the clinical relevance of the findings, they highlight the use 
of the technology as a platform to explore mouse stroma 
recruitment to the human tumor, and, critically, how this 
may influence therapeutic response. The strategy can also 
be applied routinely in pharmacodynamic studies of PDX 
models for detailed monitoring of compartment specific 
changes after treatment, ultimately leading to better efficacy 
prediction in the patient. As a resource for the pre-clinical 
model research community, all gene-level human and mouse 
expression data have been deposited in the ArrayExpress 
database (www.ebi.ac.uk/arrayexpress) under accession 
number E-MTAB-3980.
METHODS
Ethics statement
All animal studies were conducted in accordance 
with U.K. Home Office legislation, the Animal Scientific 
Procedures Act 1986, as well as the AstraZeneca Global 
Bioethics policy. All experimental work is outlined in 
project license 40/3483, which has gone through the 
AstraZeneca Ethical Review Process. Studies in the 
United States were conducted in accordance with the 
guidelines established by the internal IACUC (Institutional 
Animal Care and Use Committee) and reported following 
the ARRIVE (Animal Research: Reporting in vivo 
experiments) guidelines.
Animals
Female C.B.-17 severe combined immunodeficient 
(SCID) mice were purchased from Charles River 
Laboratories (Wilmington, MA). NOD/SCID/IL2Rγnull 
(NSG) mice were purchased from Jackson Laboratories 
(Bar Harbor, ME). Beige Nude XID mice were purchased 
from Harlan Laboratories (Madison, WI). Mice were 
housed under pathogen-free conditions in individual 
ventilated cages (IVC) at our Association for the 
Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) accredited facility in Waltham, MA. 
All animal manipulations were conducted in a biosafety 
cabinet maintained under positive pressure. 
PDX model establishment
In-house PDX models were established from fresh 
patient tissue procured from Maine Medical Center 
BioBank (Portland, ME) and consented according to 
the Human Biological Samples Policy. Samples were 
received within 24 hours of surgery, minced and implanted 
subcutaneously into either NSG or CB17 SCID mice. The 
HBXF-079 sample was implanted orthotopically. The 
CTC-174 model was developed from circulating tumor 
cells in patient blood samples procured from Conversant 
Biologics (Huntsville, AL) and consented according to the 
Human Biological Samples Policy. The cells were isolated 
and implanted into the mammary fat pad of NSG mice. 
In addition, several models were purchased from Jackson 
Laboratories (Sacramento, CA) as tumor-bearing NSG 
mice. In most cases, the models were serially transplanted 
into fresh NSG mice as fragments for expansion and 
characterization, except BR0869F. For the remaining 
models, small pieces of PDX derived tumor were 
purchased specifically for profiling from Experimental 
Pharmacology and Oncology (EPO; http://www.epo-
berlin.com), Xentech (http://www.xentech.eu) and 
Champions (http://championsoncology.com) representing 
athymic nude, SCID, or NSG mice (Table S1).
RNA extraction 
~50 mg of tissue were cut from the frozen tumors 
and RNA isolated using the Qiazol kit with a DNase 
digestion using the RNase-free DNase Kit (Qiagen) on 
the Qiacube according to manufacturer’s instructions. 
RNA concentration was measured using the NanoDrop 
ND1000 (NanoDrop), and quality determined using the 
Agilent RNA nano 6000 kit and Bioanalyzer (Agilent 
Technologies). RNA integrity numbers (RIN) for all 
samples fell between 7 and 10.
RNA-Seq data
RNA libraries were made with the Illumina TruSeq 
RNA Sample Preparation kit (un-stranded) according to 
the manufacturer’s protocol. These libraries were then 
submitted for 100 bp paired-end sequencing on the Illumina 
HiSeq 2000 platform using one lane per three to six PDX 
models. A concatenated human (GRCh37/hg19) and mouse 
(GRCm38/mm9) genome was then constructed to form a 
single genome of 43 chromosomes (23 from human and 
20 from mouse). This was indexed using StarAlign [48] 
and a “gtf” formatted file combining annotations from 
both human and mouse genes downloaded from Ensembl 
version 75 [47]. The length of donor/acceptor sequence 
(“sjdbOverhang”) either side of a splice junction was set 
to 99 bases, with all other parameters set to their defaults. 
The sequenced reads were aligned to the human-mouse 
genome using StarAlign [48] with no more than three 
mismatches across each end of the pair allowed, and reads 
mapped to multiple locations discarded. Reads whose ratio 
of mismatches to mapped length was greater than 0.10, 
and non-canonical splice junctions were also removed. All 
other parameters were set to their defaults for non-stranded 
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alignment. Since we only considered reads uniquely mapped 
to the human-mouse genome according to the mapping 
parameters above, reads mapping to both human and mouse 
genomes were automatically discarded. Therefore, the 
output of the pipeline was a set of species-specific reads 
that mapped uniquely either to the human or mouse genome.
Measurement of expression level 
The number of reads overlapping each gene 
present in both human (GRCh37) and mouse (GRCm38) 
annotation files downloaded from Ensembl version 75 [47] 
were calculated using the R Bioconductor package HTSeq 
[49] in un-stranded, union mode with all other parameters 
set to default values. For the same group of genes, 
expression based on Fragments Per Kilobase per Million 
fragments mapped (FPKM) was estimated using Cuffnorm 
with library type defined as “fr-unstranded” and all other 
parameters set to defaults [50]. Non-protein coding genes 
were ignored, as well as genes whose largest transcript 
is less that 400 bp due to potential over-estimation 
of expression across transcripts less than the average 
fragment length. For PDX model BR0555 represented by 
two biological and three technical replicates, the replicate 
whose mouse component achieved the highest ESTIMATE 
stromal score was chosen for downstream analyses. 
Where required, mouse genes names were converted to 
human and vice versa using MammalHom (http://depts.
washington.edu/l2l/mammalhom.html).
Clustering of gene expression data with 
consensus non-negative matrix factorization 
(NMF)
We applied NMF to cluster the human and mouse 
transcriptomes and identify tumor and stromal specific 
subtypes respectively. The underlying principle of NMF 
is dimensionality reduction in which a small number of 
meta-genes, each defined as a positive linear combination 
of the genes in the expression data, are identified and 
then used to group samples into clusters based on the 
gene expression pattern of the samples as positive 
linear combinations of these meta-genes. Using the R 
package NMF [51], factorization rank k was chosen by 
computing the clustering for k = 2–11 against 50 random 
initializations of both the actual and a permuted gene 
expression matrix, and selecting the k value achieving 
the largest difference between cophenetic correlation 
coefficients calculated from the actual and permutated 
data (Figure S8). For further visual confirmation of a 
sensible choice of k, consensus matrices were generated 
corresponding to different k values (Figure S9). To achieve 
stability, the NMF algorithm was then run against 200 
perturbations of each gene expression matrix at the chosen 
values of k = 9 (human) and k = 5 (mouse). 
Breast cancer differential expression analyses
PDX models
PDX model hormone receptor status was determined 
by immunohistochemistry, and broadly correlated with 
mRNA expression. Nine of the 10 TNBC PDX samples 
were basal-like and all four ER+ PDX samples luminal-B 
according to PAM50 classification [52] (Table S10) therefore 
comparisons were restricted to these two intrinsic subtypes. 
TNBC subtypes listed in Table S11A were predicted using 
TNBCtype [53] with FPKM expression values as input. 
Two tumors (HBCX7 and HBCX19) that had undergone 
metastasis were ignored. Differentially expressed genes 
were identified using the R Bioconductor package DESeq2 
[54]. “minReplicatesForReplace” was set to seven or size 
of the smallest group if one group contained less than seven 
samples. All other parameters were set as defaults. Only 
genes achieving FPKM > 1 in at least one sample were 
input to DESeq2. Differential expressed genes were defined 
as those achieving a |log
2
FC| > 1.5 and FDR < 0.05.
Patient stroma
Agilent-012391 Whole Human Genome Oligo 
Microarray G4112A expression data for a set of 45 human 
breast cancer samples whose stroma had been isolated 
from the tumor by laser micro-dissection [17] were 
downloaded from the Gene Expression Omnibus [55] 
(GSE9014). Raw expression data in the Agilent Feature 
Extraction text files were loess normalized and differential 
expression between seven TNBC and 38 ER+ samples 
calculated using the R Bioconductor package Limma [56]. 
Probesets achieving a |log
2
FC| > 1.5 and FDR < 0.05 were 
deemed differentially expressed.
UBCS
Fresh frozen breast tissue samples were obtained 
from 88 women who had surgery at the Huntsman Cancer 
Hospital from 2009–2012, including tumor tissues from 
69 breast cancer patients. One tumor sample yielded 
poor quality RNA (RIN = 2.5) and was removed from 
consideration, resulting in a panel of 68 tumor samples. 
RNA libraries were made with the Illumina TruSeq 
Stranded mRNA Sample Preparation kit with oligo 
dT selection according to the manufacturer’s protocol. 
These libraries were then submitted for 50 bp single-end 
sequencing on the Illumina HiSeq 2000 platform using 
eight samples per lane. The resulting reads were aligned to 
the human (GRCh37/hg19) genome using StarAlign [48] 
with no more than three mismatches and only uniquely 
mapped reads allowed. Reads whose ratio of mismatches to 
mapped length was greater than 0.10 were also discarded. 
All other parameters were set to their defaults for stranded 
alignment. The number of reads overlapping each gene 
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present in the human (GRCh37) annotation file downloaded 
from Ensembl version 75 [47] were calculated using the 
R Bioconductor package HTSeq [49] in stranded, union 
mode with all other parameters set to default values. The 
resulting gene-by-sample matrix consisted of 12 ER+ 
luminal B and 10 BTNBC samples. TNBC subtypes listed 
in Table S11B were predicted using TNBCtype [53] with 
FPKM expression values as input. Differentially expressed 
genes (|log
2
FC| > 1.5 and FDR < 0.05) were identified with 
DESeq2 [54] using the same protocol applied to the PDX 
models.
TCGA
TCGA gene expression data (June 2014) processed 
using the RNASeqv2 pipeline were downloaded from the 
Broad Institute GDAC Firehose (http://gdac.broadinstitute.
org) and parsed to generate a gene-by-sample matrix of 
raw counts across solid tumor samples only. Breast cancer 
samples treated with tamoxifen were discarded as were 
genes achieving a mean count < 1 across all remaining 
samples. The resulting matrix consisted of 18,488 genes 
across 79 luminal B ER+ and 54 TNBC samples as classified 
by TCGA Network [19] by PAM50 [52]. TNBC subtypes 
given in Table S11C were taken from [56]. Differential 
expression was calculated using DESeq2 [54] as for the 
PDX models.
CCLE
RMA normalized Affymetrix U133+2 expression 
data was downloaded from CCLE [18], and all non-breast 
cancer cell lines were removed as well as cell lines for 
which subtype was ambiguous according to [58]. Since 
no PDX or TCGA basal-like samples were classified as 
claudin-low, these were removed from the cell line cohort. 
The resulting gene-by-sample matrix consisted of 12 ER+ 
luminal B and seven BTNBC samples. TNBC subtypes 
given in Table S11D were taken from [23]. Genes 
achieving |log2FC| > 1.5 and T-test p-value < 0.01 were 
defined as differentially expressed. 
Note that for cross-platform comparisons, we 
considered only a core set of 15,984 genes represented on 
all platforms.
Expression data preparation for clustering and 
cross-species correlation analysis
Gene-by-sample expression matrices were generated 
for each species in which only genes achieving FPKM > 10 
(human genes) or FPKM > 2 (mouse genes) in at least one 
sample, and coefficient of variation > 0.20 were retained. The 
resulting matrix of FPKM expression values was converted 
to a non-negative matrix by addition of an arbitrary value of 
1.1 to each entry and then taking log
2
 of the result.
EMT and breast CSC signatures
The EMT signature was taken from [20] consisting of 
144 human (141 mouse) genes up-regulated and 156 human 
(142 mouse) genes down-regulated in EMT according to 
[20]. The breast CSC signature was based on the CD44+/
CD24−/low-mammosphere (MS) signature of [21] using 90 
up-regulated and 211 down-regulated human genes.
Mouse gender predictions
All genes on the Y chromosome were identified, 
and pseudogenes and genes achieving a count of < 1000 
reads across all models were removed. The remaining 
genes were manually inspected, and those with 
evidence of expression across all models and therefore 
not following the profile of the majority of genes were 
also removed. Genes contributing to the mouse gender 
prediction consisted of Eif2s3y, Ddx3y, Kdm5d and Uty. 
Read counts across these genes were summed for all 
models and the results divided by the total read count 
across all genes and multiplied by 1000 to give a Y index. 
Mice achieving Y index > 10 were classified as male, and 
female otherwise. 
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